Viatris Inc. is a global healthcare company that offers a diverse portfolio of medicines, including prescription brand drugs, generics, complex generics, and biosimilars, across various therapeutic areas such as cardiovascular health, oncology, and respiratory care. Operating in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector, Viatris has a broad international presence and distributes its products through multiple channels. The company's recent earnings performance shows a consistent pattern of beating EPS estimates in the last three reported quarters. In Q4 2025, Viatris reported EPS of $0.57, exceeding the estimate of $0.5515, with revenue at $3.704 billion, surpassing the estimate of $3.346 billion. This followed a Q3 2025 where EPS was $0.67, beating the $0.6174 estimate, and revenue reached $3.760 billion. Q2 2025 also saw an EPS beat of $0.62 against an estimate of $0.55578, with revenue at $3.582 billion. The Q1 2025 EPS was $0.50, a slight beat over the $0.49193 estimate, with revenue at $3.254 billion. The Q4 2024 EPS was $0.54, a miss against the $0.57203 estimate, with revenue at $3.528 billion. This indicates a strong trend of exceeding analyst expectations for earnings in recent quarters, coupled with revenue growth. Historical streak analysis reveals a pattern of revenue growth and consistent EPS beats in the most recent periods, with the exception of Q4 2024. Recent news indicates that Viatris received approval in Japan for Effexor® SR capsules and contributed $25 million in licensing and milestone payments related to Yupelri sales. Analysts maintain positive ratings, with Barclays holding an Overweight rating and raising their price target. The company is also highlighted for its free cash flow generation and debt paydown. Investors will be watching for continued execution of its long-term growth strategy through 2030, focusing on product launches, pipeline development, and shareholder returns. Key will be the sustained ability to deliver on EPS estimates and revenue growth, alongside managing its dividend strategy and debt reduction.
